Larimar Therapeutics: Latest News, Top Stories & Analysis - Page 2 of 2

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s Ataxia (FA), reporting key regulatory advancements, ongoing clinical developments, and a robust …

Regional

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference

March 5, 2025March 4, 2025 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled to take place in Miami Beach, Florida, from …

Regional

Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia

January 24, 2025January 23, 2025 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in …

Regional

Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment

December 19, 2024December 18, 2024 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced encouraging initial results from its ongoing open-label extension (OLE) study evaluating long-term daily injections of nomlabofusp for Friedreich’s ataxia …

Regional

Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress

November 21, 2024November 20, 2024 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) recently presented encouraging data from its studies on nomlabofusp at the International Congress for Ataxia Research in London. The data, derived …

Regional

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress

October 31, 2024October 30, 2024 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has released its financial results for the third quarter of 2024, alongside updates on its nomlabofusp program aimed at treating Friedreich’s …

Regional

Larimar Therapeutics Reports Q2 2024 Financial Results and Milestones

August 8, 2024August 8, 2024 - by Timothy Alexander

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced its second-quarter 2024 financial results and significant progress in its nomlabofusp development program.